EN DE
Watch Haemonetics Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Haemonetics Corporation (HAE) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Haemonetics Corporation stock $47.46, price $120, that is 60.4% below the price, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

HC Haemonetics Corporation logo Some data Nov 6, 2026

Haemonetics Corporation

HAE · US
Solid, but very expensive

Our calculation puts a fair price 60% below what the stock costs today.

Quality 68/100
Generates free cash flow
Positive coverage
Mixed Growth (revenue 5y +8.9 %/yr in USD)
Thin margins · 7.1% net margin (TTM)
Mixed vs. peers (6/13)
Moderate moat 51/100 · thin data
Some data
Fair value $47.46 · Strongly overvalued
High debt
Watch Haemonetics Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$127.42 $43.77 Fair Value $47.46 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $43.77 – $127.42 · fair‑value band $35.29 – $68.15 · the $119.93 price screens above the $47.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Haemonetics in your weekly email

Every Wednesday you see whether Haemonetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.

Show moreShow less

It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.

The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications.

In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions.

Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions.

It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Stock analysis

Haemonetics Corporation (HAE) currently trades at $119.93, while our model-based Fair Value estimate is $47.46, 60% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $73.91 per share, and 0 of the 22 models we run sit above the $119.93 price.

Bear case: the Earnings-Based group reads lowest at $21.75, and 22 of the 22 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $35.29 (bear) to $68.15 (bull), the price of $119.93 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Haemonetics Corporation reported revenue of $1.3B in FY2026 versus $993M in FY2022, a compound +7.7%/yr. Reported net income was $97.3M in FY2026, compounding +22.4%/yr from FY2022.

Key figures

Market cap $5.7B Mid · P/E ratio 53.1 · P/S ratio 4.20 · EPS (TTM) $2.26 · Net margin 7.1% · Return on equity 11.2% · Return on assets (EBIT) 7.8% (5-year average) · Operating margin 17.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 6% below its 52-week high and 130% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −60%, HAE screens richer than that median.

Fair Value models

Bear $35.29 Fair Value $47.46 Bull $68.15
Price $119.93 · Downside -60.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($1.38 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $50.13 $88.14 $146.13 78
Growth DCF $51.86 $86.27 $135.99 77
Owner Earnings $34.13 $63.63 $108.66 74
All 22 models by family
DCF Models
FCF DCF $50.13 $88.14 $146.13 78
Owner Earnings $34.13 $63.63 $108.66 74
5Y Revenue Exit $33.29 $60.90 $95.23 71
5Y EBITDA Exit $56.37 $103.26 $156.94 74
5Y P/E Exit $23.78 $43.46 $63.29 70
10Y Revenue Exit $37.21 $63.75 $97.61 66
10Y EBITDA Exit $53.48 $93.23 $144.47 67
10Y P/E Exit $32.60 $51.61 $73.36 63
Earnings-Based
Graham-Dodd $14.54 $40.90 $53.82 65
Lynch FV $8.28 $11.83 $15.38 61
PEG = 1.0 $8.28 $11.83 $15.38 57
EPV $23.89 $31.67 $38.55 74
Multiples
P/E Multiple $35.29 $47.05 $58.82 63
P/S Multiple $27.27 $36.36 $45.45 58
EV/EBIT $46.13 $68.68 $91.23 65
EV/EBITDA $70.13 $100.68 $131.23 67
EV/Revenue $26.76 $47.46 $68.15 52
Growth DCF
Growth DCF $51.86 $86.27 $135.99 77
Rev-Margin DCF $33.29 $61.55 $93.37 71
Economic Profit
Residual Income $16.51 $19.57 $26.90 70
ROIC Compounder $25.26 $37.68 $53.01 71
Growth Earnings
Growth-Adj P/E $28.09 $40.13 $52.17 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 68/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 43
How much profit the company makes from its sales and capital
Quality Growth 28
Are margins and returns getting better?
Cashflow 87
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 87
Does it invest with discipline instead of growing at any price?
Low Volatility 69
How calm the share price moves, does not count
Price momentum 99
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 95
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyMark W KrollDirector1,400 shares at $70.56$98,784Nov 10, 2025

Plus 18 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 72/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Start year 2021 (pandemic). Over 10 years: +3.9% a year
Revenue growth 35 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 6.8% / 20.3%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 18%
Pace: the 5-year rate starts in 2021 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +8.7% a year for the price and +2.7% for the forecasts.
Forecast 2027 (sales)+6.2%
Forecast 2028 (sales)+5.5%
Projected 2029 (sales)+5.1%
Projected 2030 (sales)+4.7%
Projected 2031 (sales)+4.2%

HAE screens overvalued: fair value 60% below the price. Compare with Abbott Laboratories, →

Recent news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Haemonetics draws potential strength from recurring disposable sales linked to plasma center platform conversions, yet its business quality remains limited by insufficient proof of durable advantages and elevated leverage.
Main risk: The lack of volume commitments in the CSL agreement poses the biggest risk by constraining the scale of recurring sales growth and overall revenue stability.
Haemonetics can tap recurring sales of disposables if CSL converts every current US plasma center to the NexSys platform by the end of 2027. The expanded agreement still offers no volume commitments and the company has kept its fiscal 2027 outlook unchanged until the November update. Will the rollout add durable growth that outpaces what is already reflected in expectations or will the phased transition and lack of guarantees keep the contribution modest?
Join the discussion →

Compare Haemonetics Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside −60.4% · Below median
Profitability
Return on equity (12 months) 11.2% · Above median
Return on assets 4.1% · Above median
Net margin (12 months) 7.1% · Above median
Operating margin (12 months) 17.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 5.6% · Below median
Balance sheet
Debt / equity 1.53× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 53.1× · Priciest 25%
P/B 7.13× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 4.20× · Pricier than median
Price / free cash flow (fiscal year) 21.8× · Cheaper than median
EV/EBITDA 18.5× · Pricier than median
PEG 2.02× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)28 · sector 35
PAST (return on equity)45 · sector 17
HEALTH (low debt)23 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs HAE
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs HAE
DexCom, Inc DXCM $79.41 $87.35 +10% vs HAE
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs HAE
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs HAE
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs HAE
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs HAE
Abbott Laboratories, ABT $109.93 $75.28 −32% vs HAE
Medtronic plc MDT $101.80 $65.61 −36% vs HAE
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs HAE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Haemonetics Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Haemonetics Corporation Fair Value". https://www.fairvalue-calculator.com/stock/HAE

Frequently asked questions

Is Haemonetics Corporation (HAE) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $47.46 versus a price of $119.93, about 60% lower (overvalued).
What is the fair value of HAE?
Our model-based fair value for Haemonetics Corporation is $47.46 (as of Nov 6, 2026), built from audited fundamentals. The current price: $119.93.
What is the quality score of HAE?
Haemonetics Corporation has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Haemonetics Corporation (HAE)?
Our model-based price target is the fair value of $47.46 (as of Nov 6, 2026) from 22 valuation models. Cautious scenario $35.29, optimistic scenario $68.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Haemonetics Corporation stock forecast for 2026?
Our models put fair value at $47.46, about 60% lower versus a price of $119.93 (overvalued). Cautious scenario $35.29, optimistic scenario $68.15. The calculation is refreshed regularly with new filings.
What is the revenue of Haemonetics Corporation (HAE)?
Haemonetics Corporation reported trailing-twelve-month revenue of about $1.4B (latest available figure, as of Nov 6, 2026).
What growth is priced into Haemonetics Corporation (HAE)?
For today's price to be fair in a discounted-cash-flow model, Haemonetics Corporation would have to grow free cash flow by +11.3 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.9 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of HAE use?
Our models discount Haemonetics Corporation at 8.7 %: a base by market capitalisation (mid), damped by beta 0.59, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Haemonetics Corporation that is +11.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Haemonetics Corporation (HAE) delivered so far?
Over the past 5 years revenue at Haemonetics Corporation grew +8.9 % a year. The price currently implies free-cash-flow growth of +11.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Haemonetics Corporation (HAE) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Haemonetics Corporation (+11.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Haemonetics Corporation (HAE)?
The free-cash-flow yield on the price is 4.59 %: that much free cash flow Haemonetics Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Haemonetics Corporation (HAE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Haemonetics Corporation it is $47.46 per share (as of Nov 6, 2026), against a price of $119.93. It is the blended result of 22 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Haemonetics Corporation stock overvalued or undervalued in 2026?
As of Nov 6, 2026, HAE trades above its calculated fair value: price $119.93, fair value $47.46, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HAE?
No. The price is what the market pays today ($119.93); the fair value is what the company's own numbers justify ($47.46). For Haemonetics Corporation the two are $72.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Haemonetics Corporation worth?
The market values Haemonetics Corporation at about $5.7B (market capitalisation, as of Nov 6, 2026). Per share that is $119.93; our models calculate a fair value of $47.46 per share.
What do the bullish and bearish scenarios say about HAE?
Our models span a range for Haemonetics Corporation: cautious scenario $35.29, base $47.46, optimistic $68.15 per share (as of Nov 6, 2026, price $119.93). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HAE?
Haemonetics Corporation trades at a price-to-earnings ratio of 53.1 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $47.46 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2018 to 2026), reported earnings: 67.5. Other multiples: PEG 2.0, P/B 7.1, P/S 4.2, EV/EBITDA 18.5.
What is the PEG ratio of HAE?
The PEG ratio of Haemonetics Corporation is 2.02 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Haemonetics Corporation (HAE)?
Balance-sheet figures for Haemonetics Corporation (as of Nov 6, 2026): return on equity 11.2%, debt of 1.53 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is HAE from its 52-week high?
Haemonetics Corporation trades at $119.93, about 6% below its 52-week high of $127.42 and 130% above the low of $52.24 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $47.46 is for.
Which stocks are comparable to Haemonetics Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Haemonetics Corporation stock attractive at the current price?
The data as of Nov 6, 2026: price $119.93, calculated fair value $47.46 (−60%), Quality Score 68/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HAE calculated?
We run Haemonetics Corporation through 22 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $47.46 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Haemonetics Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Haemonetics Corporation (HAE)?
The closing price on Nov 6, 2026 was $119.93. Our model-based fair value is $47.46, about 60% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Haemonetics Corporation right now?
The price sits above even our optimistic bull case ($68.15). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($35.29 to $68.15) leaves room in how you read the outcome.

Key figures of Haemonetics Corporation

How large is the market capitalisation of Haemonetics Corporation (HAE)?
The market capitalisation of Haemonetics Corporation is $5.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Haemonetics Corporation (HAE)?
The price-to-sales ratio of Haemonetics Corporation is 4.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Haemonetics Corporation (HAE)?
Earnings per share at Haemonetics Corporation are $2.26 (price ÷ EPS = P/E 53.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Haemonetics Corporation (HAE)?
The net margin of Haemonetics Corporation is 7.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Haemonetics Corporation (HAE)?
The return on equity (ROE) of Haemonetics Corporation is 11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Haemonetics Corporation (HAE)?
On an EBIT basis the return on assets of Haemonetics Corporation is 7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Haemonetics Corporation (HAE)?
The operating margin of Haemonetics Corporation is 17.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Haemonetics Corporation (HAE)?
Revenue at Haemonetics Corporation is growing +5.6% versus a year earlier (3y avg +4.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Haemonetics Corporation (HAE)?
Earnings per share at Haemonetics Corporation are growing +2.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Haemonetics Corporation (HAE) carry?
The net debt of Haemonetics Corporation is $979M (fiscal year 2026, ≈ 3.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Haemonetics Corporation in the live analysis

One click puts Haemonetics Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.